Physician profile
Danielle Bruno
NPI 1497022107
$61,472.45
in general payments reported to CMS, 2019-2025
59 companies · $9,142 in 2025
The $9,142 reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $13K · 2022: $17K · 2023: $11K · 2024: $12K · 2025: $9,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Food and Beverage: $10K · Consulting Fee: $6,478 · Honoraria: $1,860 · Travel and Lodging: $1,034 · Education: $46.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,000.00 |
| Food and Beverage | $10,419.58 |
| Consulting Fee | $6,478.00 |
| Honoraria | $1,860.00 |
| Travel and Lodging | $1,033.92 |
| Education | $46.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,395.48 | 2021-2025 | |
| Impel Pharmaceuticals INC. | $5,584.61 | 2022-2023 | Trudhesa |
| Biohaven Pharmaceutical Holding Company Ltd. | $4,642.41 | 2022 | |
| Lilly USA, LLC | $3,633.36 | 2021-2025 | Emgality, Reyvow, Zepbound |
| Biohaven Pharmaceuticals, INC. | $3,380.71 | 2021 | |
| Lundbeck LLC | $1,892.40 | 2021-2025 | Vyepti |
| Medtronic, INC. | $1,169.77 | 2022-2024 | Percept Pc Brainsense |
| Tonix Medicines, INC. | $1,080.84 | 2023-2025 | Zembrace Symtouch |
| Teva Pharmaceuticals USA, INC. | $957.90 | 2021-2024 | Ajovy, Austedo Xr, Austedo |
| Pfizer INC. | $798.17 | 2023-2025 | |
| Ucb, INC. | $600.18 | 2021-2025 | Briviact, Nayzilam, Rystiggo |
| Biogen, INC. | $573.77 | 2021-2023 | Vumerity, Tysabri, Plegridy |
| Genentech USA, INC. | $521.92 | 2022-2025 | Ocrevus Zunovo, Ocrevus |
| Allergan, INC. | $513.82 | 2021-2022 | |
| Emd Serono, INC. | $451.63 | 2021-2025 | Mavenclad, Mavenclad |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Bruno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.